Boundless Bio Financials

BOLD Stock

USD 1.26 0.02 1.61%

Based on the analysis of Boundless Bio's profitability, liquidity, and operating efficiency, Boundless Bio Common is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February. At present, Boundless Bio's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 9.5 M, whereas Total Stockholder Equity is forecasted to decline to about 71.1 M.

Cash Flow Balance Sheet Income Statement

Covid

Boundless Bio Balance Sheet Chart

At present, Boundless Bio's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 9.5 M, whereas Total Stockholder Equity is forecasted to decline to about 71.1 M.

Total Assets Short Long Term Debt Total Total Current Liabilities Property Plant And Equipment Net

Key indicators impacting Boundless Bio's financial strength include:

Current Value

Last Year

Change From Last Year

10 Year Trend

Current Ratio

10.78

17.08

Way Down

Slightly volatile

Investors should never underestimate Boundless Bio's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Boundless Bio's cash flow, debt, and profitability to make informed and accurate decisions about investing in Boundless Bio Common.

Net Income

(78.93 Million)

Build AI portfolio with Boundless Stock

Understanding current and past Boundless Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Boundless Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Boundless Bio's assets may result in an increase in income on the income statement.

Please note, the presentation of Boundless Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Boundless Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Boundless Bio's management manipulating its earnings.

Boundless Bio Stock Summary

Boundless Bio competes with Q32 Bio, NextCure, Plus Therapeutics, Intensity Therapeutics, and Iterum Therapeutics. Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California. Audentes Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people.

Specialization	Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Instrument	USA Stock View All
Exchange	NASDAQ Exchange
ISIN	US10170A1007
Business Address	10955 Alexandria Way,
Sector	Biotechnology
Industry	Health Care
Benchmark	Dow Jones Industrial
Website	boundlessbio.com
Phone	858 766 9912
Currency	USD - US Dollar

Boundless Bio Key Financial Ratios

	Return On Equity	-0.45
	EBITDA	(64.28 M)
	Net Income	(65.36 M)
	Cash Per Share	7.68 X
	Debt To Equity	0.08 %

More Fundamentals

Boundless Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Boundless Bio's current stock value. Our valuation model uses many indicators to compare Boundless Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Boundless Bio competition to find correlations between indicators driving Boundless Bio's intrinsic value. More Info.

Boundless Bio Common is rated third in return on equity category among its peers. It is number one stock in return on asset category among its peers . At present, Boundless Bio's Return On Equity is projected to increase slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Boundless Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Most indicators from Boundless Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Boundless Bio Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boundless Bio Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

As of January 15, 2026, Selling General Administrative is expected to decline to about 11.9 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 81.9 M

	2023	2024	2025	2026 (projected)
Interest Income	5.3M	7.9M	9.1M	9.5M
Net Interest Income	5.3M	7.9M	9.1M	9.5M

Interest Income Net Interest Income

Boundless Bio fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Good Will	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Capital Lease Obligations
Total Assets		0.16	-0.43	0.72	0.85	0.39	0.85	-0.64	-0.78	0.87	0.93	0.56	0.84	0.99	-0.01	0.67	0.97	-0.35	0.65	0.64	-0.34	0.99	0.33	-0.01	0.28	0.09
Short Long Term Debt Total	0.16		0.65	-0.15	0.17	0.93	0.14	0.64	-0.64	-0.25	-0.12	0.26	-0.31	0.14	-0.8	-0.01	0.26	-0.02	-0.24	0.8	-0.03	0.13	0.45	-0.8	-0.45	0.99
Other Current Liab	-0.43	0.65		-0.52	-0.33	0.49	-0.5	0.82	-0.01	-0.69	-0.6	-0.25	-0.77	-0.42	-0.58	-0.6	-0.3	0.16	-0.39	0.19	0.15	-0.42	-0.16	-0.58	-0.43	0.71
Total Current Liabilities	0.72	-0.15	-0.52		0.82	0.21	0.78	-0.63	-0.59	0.91	0.71	0.22	0.86	0.74	0.14	0.3	0.71	-0.65	0.92	0.15	-0.62	0.74	0.29	0.14	0.77	-0.24
Total Stockholder Equity	0.85	0.17	-0.33	0.82		0.5	0.67	-0.52	-0.69	0.78	0.78	0.68	0.8	0.81	-0.02	0.26	0.78	-0.79	0.74	0.44	-0.78	0.81	0.17	-0.02	0.62	0.09
Property Plant And Equipment Net	0.39	0.93	0.49	0.21	0.5		0.33	0.41	-0.79	0.04	0.12	0.4	-0.01	0.36	-0.73	-0.01	0.46	-0.36	0.1	0.79	-0.36	0.35	0.44	-0.73	-0.09	0.89
Current Deferred Revenue	0.85	0.14	-0.5	0.78	0.67	0.33		-0.5	-0.82	0.85	0.74	0.23	0.78	0.88	-0.01	0.74	0.9	-0.22	0.58	0.57	-0.19	0.88	0.7	-0.01	0.23	0.06
Net Debt	-0.64	0.64	0.82	-0.63	-0.52	0.41	-0.5		0.09	-0.84	-0.84	-0.24	-0.88	-0.65	-0.51	-0.53	-0.51	0.24	-0.65	0.11	0.22	-0.65	0.16	-0.51	-0.54	0.69
Retained Earnings	-0.78	-0.64	-0.01	-0.59	-0.69	-0.79	-0.82	0.09		-0.57	-0.57	-0.34	-0.47	-0.79	0.49	-0.49	-0.86	0.27	-0.45	-0.86	0.25	-0.79	-0.68	0.49	-0.05	-0.57
Accounts Payable	0.87	-0.25	-0.69	0.91	0.78	0.04	0.85	-0.84	-0.57		0.91	0.31	0.97	0.89	0.25	0.6	0.83	-0.42	0.83	0.24	-0.4	0.89	0.26	0.25	0.59	-0.33
Cash	0.93	-0.12	-0.6	0.71	0.78	0.12	0.74	-0.84	-0.57	0.91		0.48	0.92	0.93	0.09	0.68	0.84	-0.32	0.68	0.42	-0.3	0.93	0.11	0.09	0.38	-0.19
Non Current Assets Total	0.56	0.26	-0.25	0.22	0.68	0.4	0.23	-0.24	-0.34	0.31	0.48		0.41	0.45	0.03	0.2	0.41	-0.53	0.16	0.42	-0.55	0.45	0.03	0.03	0.18	0.21
Non Currrent Assets Other	0.84	-0.31	-0.77	0.86	0.8	-0.01	0.78	-0.88	-0.47	0.97	0.92	0.41		0.84	0.29	0.59	0.75	-0.49	0.76	0.19	-0.47	0.84	0.18	0.29	0.61	-0.39
Cash And Short Term Investments	0.99	0.14	-0.42	0.74	0.81	0.36	0.88	-0.65	-0.79	0.89	0.93	0.45	0.84		-0.01	0.69	0.98	-0.29	0.67	0.63	-0.27	1.0	0.36	-0.01	0.26	0.07
Good Will	-0.01	-0.8	-0.58	0.14	-0.02	-0.73	-0.01	-0.51	0.49	0.25	0.09	0.03	0.29	-0.01		0.02	-0.07	-0.08	0.21	-0.62	-0.09	-0.01	-0.29	1.0	0.36	-0.8
Common Stock Shares Outstanding	0.67	-0.01	-0.6	0.3	0.26	-0.01	0.74	-0.53	-0.49	0.6	0.68	0.2	0.59	0.69	0.02		0.66	0.31	0.12	0.55	0.32	0.69	0.56	0.02	-0.24	-0.05
Short Term Investments	0.97	0.26	-0.3	0.71	0.78	0.46	0.9	-0.51	-0.86	0.83	0.84	0.41	0.75	0.98	-0.07	0.66		-0.26	0.63	0.7	-0.24	0.98	0.47	-0.07	0.19	0.19
Non Current Liabilities Total	-0.35	-0.02	0.16	-0.65	-0.79	-0.36	-0.22	0.24	0.27	-0.42	-0.32	-0.53	-0.49	-0.29	-0.08	0.31	-0.26		-0.6	0.04	1.0	-0.29	0.12	-0.08	-0.83	0.05
Other Current Assets	0.65	-0.24	-0.39	0.92	0.74	0.1	0.58	-0.65	-0.45	0.83	0.68	0.16	0.76	0.67	0.21	0.12	0.63	-0.6		0.0	-0.57	0.68	0.01	0.21	0.81	-0.32
Other Stockholder Equity	0.64	0.8	0.19	0.15	0.44	0.79	0.57	0.11	-0.86	0.24	0.42	0.42	0.19	0.63	-0.62	0.55	0.7	0.04	0.0		0.04	0.62	0.59	-0.62	-0.4	0.77
Total Liab	-0.34	-0.03	0.15	-0.62	-0.78	-0.36	-0.19	0.22	0.25	-0.4	-0.3	-0.55	-0.47	-0.27	-0.09	0.32	-0.24	1.0	-0.57	0.04		-0.28	0.13	-0.09	-0.81	0.04
Total Current Assets	0.99	0.13	-0.42	0.74	0.81	0.35	0.88	-0.65	-0.79	0.89	0.93	0.45	0.84	1.0	-0.01	0.69	0.98	-0.29	0.68	0.62	-0.28		0.36	-0.01	0.27	0.06
Short Term Debt	0.33	0.45	-0.16	0.29	0.17	0.44	0.7	0.16	-0.68	0.26	0.11	0.03	0.18	0.36	-0.29	0.56	0.47	0.12	0.01	0.59	0.13	0.36		-0.29	-0.23	0.4
Intangible Assets	-0.01	-0.8	-0.58	0.14	-0.02	-0.73	-0.01	-0.51	0.49	0.25	0.09	0.03	0.29	-0.01	1.0	0.02	-0.07	-0.08	0.21	-0.62	-0.09	-0.01	-0.29		0.36	-0.8
Common Stock	0.28	-0.45	-0.43	0.77	0.62	-0.09	0.23	-0.54	-0.05	0.59	0.38	0.18	0.61	0.26	0.36	-0.24	0.19	-0.83	0.81	-0.4	-0.81	0.27	-0.23	0.36		-0.51
Capital Lease Obligations	0.09	0.99	0.71	-0.24	0.09	0.89	0.06	0.69	-0.57	-0.33	-0.19	0.21	-0.39	0.07	-0.8	-0.05	0.19	0.05	-0.32	0.77	0.04	0.06	0.4	-0.8	-0.51

Click cells to compare fundamentals

Boundless Bio Account Relationship Matchups

Today, most investors in Boundless Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Boundless Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Boundless Bio growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.0112)

At present, Boundless Bio's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.

Boundless Bio January 15, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Boundless Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Boundless Bio Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of Boundless Bio Common based on widely used predictive technical indicators. In general, we focus on analyzing Boundless Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Boundless Bio's daily price indicators and compare them against related drivers.

	Downside Deviation	3.45
	Information Ratio	(0.02)
	Maximum Drawdown	16.75
	Value At Risk	(5.11)
	Potential Upside	5.41

Complementary Tools for Boundless Stock analysis

When running Boundless Bio's price analysis, check to measure Boundless Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boundless Bio is operating at the current time. Most of Boundless Bio's value examination focuses on studying past and present price action to predict the probability of Boundless Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boundless Bio's price. Additionally, you may evaluate how the addition of Boundless Bio to your portfolios can decrease your overall portfolio volatility.

	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Boundless Bio Financials

Boundless Bio Balance Sheet Chart

Net Income

(78.93 Million)

Boundless Bio Stock Summary

Boundless Bio Key Financial Ratios

Boundless Financial Ratios Relationships

Boundless Bio fundamental ratios Correlations

Boundless Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Price Earnings To Growth Ratio

(0.0112)

Boundless Bio January 15, 2026 Opportunity Range

Complementary Tools for Boundless Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Intangible Assets	+ 1.0	Good Will
Total Liab	+ 1.0	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Capital Lease Obligations	+ 0.99	Short Long Term Debt Total

Non Currrent Assets Other	- 0.88	Net Debt
Other Stockholder Equity	- 0.86	Retained Earnings
Short Term Investments	- 0.86	Retained Earnings
Cash	- 0.84	Net Debt
Accounts Payable	- 0.84	Net Debt
Common Stock	- 0.83	Non Current Liabilities Total